GB2528399B
(en )
2016-03-02
Catalyst and method for its preparation
GB2488674B
(en )
2015-06-03
Catalyst and method of preparation
ZA201206832B
(en )
2014-03-26
Novel peptides and method for their preparation and use
EP2549623A4
(en )
2016-08-24
ROTOR AND MANUFACTURING METHOD THEREFOR
PL2609120T3
(pl )
2016-03-31
Ulepszony sposób wytwarzania sugammadeksu
EP2657188A4
(en )
2016-11-09
FLUOROGRAPHIC AND METHOD FOR PREPARING THE SAME
IL222576A0
(en )
2012-12-31
Fexofenadine-based composition and preparation process therefor
AP3222A
(en )
2015-04-30
Germination-stimulant carbamate derivatives and process for preparation thereof
EP2635621A4
(en )
2014-07-02
HYDROSILICON RESIN AND METHOD FOR THE PRODUCTION THEREOF
EP2578725A4
(en )
2014-01-22
COATED ELEMENT AND METHOD FOR PRODUCING THE SAME
IL227711A0
(en )
2013-09-30
Phenyl-isoxazole history and their preparation process
IL231505A0
(en )
2014-04-30
Pharmaceutical preparation and method for its production
IL223180A0
(en )
2013-02-03
Agomelatine intermediates and preparation method thereof
EP2546243A4
(en )
2013-09-18
METHOD FOR THE PRODUCTION OF ALISKIRES AND INTERMEDIATE PRODUCTS THEREOF
IL225915A0
(en )
2013-06-27
5-trifluoromethyl-4-nitro-2-isoxazoline compounds and their preparation process
IL232036A0
(en )
2014-05-28
A new process for the preparation of acylguanidines and acylthioureas
GB2516380B
(en )
2015-11-18
Catalyst and method of preparation
GB201015986D0
(en )
2010-11-03
Process and apparatus
PL391463A1
(pl )
2011-12-19
Nowe, cykliczne kwasy hydroksamowe i sposób ich wytwarzania
ZA201108148B
(en )
2012-12-27
Triazine-aryl-bis-indoles and process for preparation thereof
SG11201402309YA
(en )
2014-09-26
Process for medical components and uses thereof
GB201110471D0
(en )
2011-08-03
Method and apparatus for the production of an arabinoxylan-enriched preparation and other co-products
PL392867A1
(pl )
2012-05-07
Octany cykloheksyloamoniowe i sposób ich wytwarzania
HU1000498D0
(en )
2010-11-29
New salts and preparation process thereof
PL391702A1
(pl )
2012-01-02
Sposób otrzymywania 5-hydroksykreatyniny i N-metyloguanidyny